-
MPM Capital L.P.
Distance: 0.6 Mi111 Huntington Ave Fl 31
2199 Boston -
Graffinity Pharmaceuticals AG
Distance: 0.6 Mi111 Huntington Ave Ste 610
02199-7626 Boston -
Pharma Connections Worldwide LLC
Distance: 0.8 Mi245 First St
02142 Cambridge -
Molecular Insight Pharmaceuticals, Inc.
Distance: 1.1 Mi160 2nd St
2142 Cambridge -
Satori Pharmaceuticals Inc
Distance: 1.1 Mi75 Rogers St
02142-1118 Cambridge
Website Links
Description
Igenica Biotherapeutics, Inc. is an innovative biotherapeutic company focused on the discovery and development of antibody-drug conjugates (ADCs). Igenica is the only biopharmaceutical company that fully powers the ADC development spectrum from a patient-based approach to target, and functional antibody discovery to homogeneous ADC generation and manufacturing, enabling the accelerated development and delivery of effective therapies to patients.
SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABA A and NMDA receptors, which have demonstrated preclinical activity.
The people who join our portfolio companies are critical to launching and building innovative companies and achieving our mission of making a difference for patients. We continue to grow and nurture a rich network that brings together the industry’s best in science, business, strategy and medicine. Our success in matching exceptional people with our exceptional companies is a strategic differentiator within the venture community.
Alnara Pharmaceuticals is a biopharmaceutical company dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream.
NinePoint Medical is positioned to improve patient care through the development of medical devices that enable high resolution in-vivo imaging. The company was founded on the ideal of convergence, of developing products that could bring together access, diagnosis and treatment. Founded in 2009 with an initial Series A of $33 million, the company licensed the fundamental optical coherence tomography (OCT) technology from Massachusetts General Hospital (MGH) in 2010 and received its first 510(k) clearance from the U.S. Food and Drug Administration in December 2011.